Licensing · MENA · Announced 3 Feb 2026
Bio-Thera Solutions → Avalon Pharma
Licensing deal between Bio-Thera Solutions (China) and Avalon Pharma (Saudi Arabia), covering Pembrolizumab, announced 3 Feb 2026. Value: Undisclosed.
Parties: Bio-Thera Solutions, Ltd. (China) → Avalon Pharma (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Saudi Arabia and the wider MENA region
- Therapeutic area
- Oncology
- Asset
- Pembrolizumab
- Announced
- 3 Feb 2026
Our analysis
Why this matters.
In February 2026, China's Bio-Thera Solutions licensed MENA commercial rights for BAT3306 — its proposed biosimilar to Keytruda (pembrolizumab) , the world's best-selling medicine at roughly $30bn a year — to Saudi Arabia's Avalon Pharma .
The full analysis is free to read with a work email on this page.
Source: Bio-Thera